Hemispherx Biopharma, Inc.
(NYSE Amex Equities : HEB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.79%83.270.9%$976.48m
KITEKite Pharma, Inc.
-0.05%179.3016.1%$742.08m
CELGCelgene Corporation
0.08%143.891.1%$497.73m
AMGNAmgen Inc.
-0.47%185.761.1%$483.16m
BIIBBiogen Inc.
1.09%318.461.2%$422.36m
REGNRegeneron Pharmaceuticals, Inc.
-0.17%432.722.7%$354.34m
ALNYAlnylam Pharmaceuticals, Inc
0.78%113.8010.7%$245.72m
JUNOJuno Therapeutics, Inc.
8.46%45.1414.6%$236.75m
ALXNAlexion Pharmaceuticals, Inc.
-0.07%142.821.9%$228.97m
VRTXVertex Pharmaceuticals Incorporated
-0.53%151.261.9%$211.37m
INCYIncyte Corporation
-3.65%110.852.6%$207.65m
ILMNIllumina, Inc.
0.58%201.413.5%$159.41m
BLUEBluebird Bio, Inc.
0.70%128.7519.3%$141.45m
BMRNBioMarin Pharmaceutical Inc.
1.64%94.954.4%$137.39m
CLVSClovis Oncology, Inc.
2.09%78.5618.0%$136.44m

Company Profile

Hemispherx Biopharma, Inc. operates as a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Philadelphia, PA.